NIPT can be offered to all pregnant people. Find out what resources exist.
Watch our Webinar: “Broader adoption of NIPT: Implications for Health Systems”
In August 2020, ACOG/SMFM issued guidelines recommending cfDNA (NIPT) be offered to all patients regardless of maternal age or baseline risk. Watch our webinar to learn more.
Recent ACOG guidelines support NIPT for all pregnancies1
- Recommends NIPT as an option to be “discussed and offered to all patients early in pregnancy, regardless of maternal age or baseline risk.”
- Endorses cfDNA as the “most sensitive and specific screening test for the common fetal aneuploidies.”
- Highlights unique advantages of SNP-based NIPT, including triploidy detection and unique twins capabilities such as zygosity detection and individual fetal fraction measurements.
Insurers now broadly cover NIPT for average risk
Major private health insurance companies including UnitedHealthcare, Aetna, Humana, and Centene have recently updated their policy guidelines to extend NIPT coverage to all expectant women.2
Panorama is highly aligned with ACOG Practice Bulletin 226
| PANORAMA’S AREAS OF UNIQUE CLINICAL VALUE | ACOG PRACTICE BULLETIN 226 HIGHLIGHTS1 | PANORAMA SNP-BASED NIPT3,4,5,6 | |
|---|---|---|---|
| Twins differentiation |  |
“Cell-free DNA [NIPT] can be performed in twin pregnancies“ |  |
| “…one laboratory method which uses SNP analysis reports zygosity as well as individual fetal fractions.“ | |
||
| Every result matters |  |
“[In twin gestations,] it is possible that an aneuploid fetus would contribute less fetal DNA, therefore masking the aneuploid result.” | |
| Highlights known sources of false positives for most NIPTs: Vanishing twin | Maternal mosaicism |
Addressed | ||
| Accuracy and reliability |  |
“Of the [NIPT] methods, the [SNP-based] method can identify triploidy.” | |
| “…the lower prevalence of fetal trisomies in younger patients results in…a lower PPV…” | Robust clinical PPVs published |
Proven performance in average risk pregnancies
Strong clinical evidence with robust PPVs regardless of age, based on a large outcomes study with >700,000 patients under <35.
Panorama clinical outcomes in a study of over 1 million patients:
NateraCore services support providers and patients at every step
Comprehensive services to seamlessly integrate high quality testing into routine practice.
Natera Sync
Direct with your EMR
NateraSync is a flexibile solution suite built to securely integrate with your EMR and deliver end-to-end workflow efficiency.Natera Academy
On-demand educational options
Created by Natera's Medical Directors and Genetic Counselors, Natera Academy offers educational resources for healthcare providers.References
1ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
3Dar et al. Multicenter prospective study of SNP-based cfDNA screening for aneuploidy with genetic confirmation in 18,497 pregnancies. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021
4Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8
5Nicolaides et al. Prenat Diagn. 2013 June; 33(6):575-9
6Ryan et al. Fetal Diagn Ther. 2016;40(3):219-223
7DiNonno W. et al. J Clin Med. 2019 Aug; 8,1311
8Natera internal data on file